Clinical Trial Update: Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 trial evaluating capecitabine in combination with lapatinib for patients with untreated gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Capecitabine (Xeloda) (Capecitabine)
• Lapatinib (Tykerb) (lapatinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms, Gastrointestinal Tract | Phase 2 | Status: COMPLETED | Results posted: 2012-10-01